The global Oncolytic Virus Therapy market size was valued at US$ 9.6 million in 2024 and is forecast to a readjusted size of USD 43.4 million by 2031 with a CAGR of 24.3% during review period.
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn鈥檛 until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.
North America and Europe are the main markets, each accounting for about 40% of the market.
This report is a detailed and comprehensive analysis for global Oncolytic Virus Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oncolytic Virus Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
Global Oncolytic Virus Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Oncolytic Virus Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Oncolytic Virus Therapy market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oncolytic Virus Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oncolytic Virus Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Oncolytic Virus Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Vaccinia Virus-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses
麻豆原创 segment by Application
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Others
麻豆原创 segment by players, this report covers
Amgen
Oncolytics Biotech
Viralytics
Transgene SA
Oncolys BioPharma
Targovax
PsiOxus Therapeutics
SillaJen Biotherapeutics
Sorrento Therapeutics
Lokon Pharma
Genelux Corporation
Vyriad
TILT Biotherapeutics
Cold Genesys
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Oncolytic Virus Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Oncolytic Virus Therapy, with revenue, gross margin, and global market share of Oncolytic Virus Therapy from 2020 to 2025.
Chapter 3, the Oncolytic Virus Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Oncolytic Virus Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oncolytic Virus Therapy.
Chapter 13, to describe Oncolytic Virus Therapy research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Oncolytic Virus Therapy by Type
1.3.1 Overview: Global Oncolytic Virus Therapy 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Oncolytic Virus Therapy Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 HSV-based Oncolytic Viruses
1.3.4 Adenoviruses-based Oncolytic Viruses
1.3.5 Vaccinia Virus-based Oncolytic Viruses
1.3.6 Vesicular Stomatitis Virus-based Oncolytic Viruses
1.3.7 Newcastle Disease Virus-based Oncolytic Viruses
1.4 Global Oncolytic Virus Therapy 麻豆原创 by Application
1.4.1 Overview: Global Oncolytic Virus Therapy 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Melanoma
1.4.3 Prostate Cancer
1.4.4 Breast Cancer
1.4.5 Ovarian Cancer
1.4.6 Others
1.5 Global Oncolytic Virus Therapy 麻豆原创 Size & Forecast
1.6 Global Oncolytic Virus Therapy 麻豆原创 Size and Forecast by Region
1.6.1 Global Oncolytic Virus Therapy 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Oncolytic Virus Therapy 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Oncolytic Virus Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Oncolytic Virus Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Oncolytic Virus Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Oncolytic Virus Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Oncolytic Virus Therapy 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Oncolytic Virus Therapy Product and Solutions
2.1.4 Amgen Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Amgen Recent Developments and Future Plans
2.2 Oncolytics Biotech
2.2.1 Oncolytics Biotech Details
2.2.2 Oncolytics Biotech Major Business
2.2.3 Oncolytics Biotech Oncolytic Virus Therapy Product and Solutions
2.2.4 Oncolytics Biotech Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Oncolytics Biotech Recent Developments and Future Plans
2.3 Viralytics
2.3.1 Viralytics Details
2.3.2 Viralytics Major Business
2.3.3 Viralytics Oncolytic Virus Therapy Product and Solutions
2.3.4 Viralytics Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Viralytics Recent Developments and Future Plans
2.4 Transgene SA
2.4.1 Transgene SA Details
2.4.2 Transgene SA Major Business
2.4.3 Transgene SA Oncolytic Virus Therapy Product and Solutions
2.4.4 Transgene SA Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Transgene SA Recent Developments and Future Plans
2.5 Oncolys BioPharma
2.5.1 Oncolys BioPharma Details
2.5.2 Oncolys BioPharma Major Business
2.5.3 Oncolys BioPharma Oncolytic Virus Therapy Product and Solutions
2.5.4 Oncolys BioPharma Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Oncolys BioPharma Recent Developments and Future Plans
2.6 Targovax
2.6.1 Targovax Details
2.6.2 Targovax Major Business
2.6.3 Targovax Oncolytic Virus Therapy Product and Solutions
2.6.4 Targovax Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Targovax Recent Developments and Future Plans
2.7 PsiOxus Therapeutics
2.7.1 PsiOxus Therapeutics Details
2.7.2 PsiOxus Therapeutics Major Business
2.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Product and Solutions
2.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 PsiOxus Therapeutics Recent Developments and Future Plans
2.8 SillaJen Biotherapeutics
2.8.1 SillaJen Biotherapeutics Details
2.8.2 SillaJen Biotherapeutics Major Business
2.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Product and Solutions
2.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 SillaJen Biotherapeutics Recent Developments and Future Plans
2.9 Sorrento Therapeutics
2.9.1 Sorrento Therapeutics Details
2.9.2 Sorrento Therapeutics Major Business
2.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Product and Solutions
2.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Sorrento Therapeutics Recent Developments and Future Plans
2.10 Lokon Pharma
2.10.1 Lokon Pharma Details
2.10.2 Lokon Pharma Major Business
2.10.3 Lokon Pharma Oncolytic Virus Therapy Product and Solutions
2.10.4 Lokon Pharma Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Lokon Pharma Recent Developments and Future Plans
2.11 Genelux Corporation
2.11.1 Genelux Corporation Details
2.11.2 Genelux Corporation Major Business
2.11.3 Genelux Corporation Oncolytic Virus Therapy Product and Solutions
2.11.4 Genelux Corporation Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Genelux Corporation Recent Developments and Future Plans
2.12 Vyriad
2.12.1 Vyriad Details
2.12.2 Vyriad Major Business
2.12.3 Vyriad Oncolytic Virus Therapy Product and Solutions
2.12.4 Vyriad Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Vyriad Recent Developments and Future Plans
2.13 TILT Biotherapeutics
2.13.1 TILT Biotherapeutics Details
2.13.2 TILT Biotherapeutics Major Business
2.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Product and Solutions
2.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 TILT Biotherapeutics Recent Developments and Future Plans
2.14 Cold Genesys
2.14.1 Cold Genesys Details
2.14.2 Cold Genesys Major Business
2.14.3 Cold Genesys Oncolytic Virus Therapy Product and Solutions
2.14.4 Cold Genesys Oncolytic Virus Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Cold Genesys Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Oncolytic Virus Therapy Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Oncolytic Virus Therapy by Company Revenue
3.2.2 Top 3 Oncolytic Virus Therapy Players 麻豆原创 Share in 2024
3.2.3 Top 6 Oncolytic Virus Therapy Players 麻豆原创 Share in 2024
3.3 Oncolytic Virus Therapy 麻豆原创: Overall Company Footprint Analysis
3.3.1 Oncolytic Virus Therapy 麻豆原创: Region Footprint
3.3.2 Oncolytic Virus Therapy 麻豆原创: Company Product Type Footprint
3.3.3 Oncolytic Virus Therapy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Oncolytic Virus Therapy Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Oncolytic Virus Therapy 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Oncolytic Virus Therapy Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Oncolytic Virus Therapy 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Oncolytic Virus Therapy Consumption Value by Type (2020-2031)
6.2 North America Oncolytic Virus Therapy 麻豆原创 Size by Application (2020-2031)
6.3 North America Oncolytic Virus Therapy 麻豆原创 Size by Country
6.3.1 North America Oncolytic Virus Therapy Consumption Value by Country (2020-2031)
6.3.2 United States Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Oncolytic Virus Therapy Consumption Value by Type (2020-2031)
7.2 Europe Oncolytic Virus Therapy Consumption Value by Application (2020-2031)
7.3 Europe Oncolytic Virus Therapy 麻豆原创 Size by Country
7.3.1 Europe Oncolytic Virus Therapy Consumption Value by Country (2020-2031)
7.3.2 Germany Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Therapy Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Oncolytic Virus Therapy Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Oncolytic Virus Therapy 麻豆原创 Size by Region
8.3.1 Asia-Pacific Oncolytic Virus Therapy Consumption Value by Region (2020-2031)
8.3.2 China Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Oncolytic Virus Therapy Consumption Value by Type (2020-2031)
9.2 South America Oncolytic Virus Therapy Consumption Value by Application (2020-2031)
9.3 South America Oncolytic Virus Therapy 麻豆原创 Size by Country
9.3.1 South America Oncolytic Virus Therapy Consumption Value by Country (2020-2031)
9.3.2 Brazil Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Therapy Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Oncolytic Virus Therapy Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Oncolytic Virus Therapy 麻豆原创 Size by Country
10.3.1 Middle East & Africa Oncolytic Virus Therapy Consumption Value by Country (2020-2031)
10.3.2 Turkey Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Oncolytic Virus Therapy 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Oncolytic Virus Therapy 麻豆原创 Drivers
11.2 Oncolytic Virus Therapy 麻豆原创 Restraints
11.3 Oncolytic Virus Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Oncolytic Virus Therapy Industry Chain
12.2 Oncolytic Virus Therapy Upstream Analysis
12.3 Oncolytic Virus Therapy Midstream Analysis
12.4 Oncolytic Virus Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Amgen
Oncolytics Biotech
Viralytics
Transgene SA
Oncolys BioPharma
Targovax
PsiOxus Therapeutics
SillaJen Biotherapeutics
Sorrento Therapeutics
Lokon Pharma
Genelux Corporation
Vyriad
TILT Biotherapeutics
Cold Genesys
听
听
*If Applicable.
